Research and Markets: Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/v246fr/latuda) has announced the addition of the "Latuda (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Latuda is a mixed D2/5-HT2A receptor antagonist with additional activity on 5-HT7 receptors. Unlike Fanapt, Latuda does not act on muscarinic or histaminergic receptors, and is thus associated with lower risks of weight gain and metabolic disturbances. Latuda is promoted as a drug that is pro-cognitive in nature and may help to relieve some of the cognitive deficits in schizophrenic patients.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Latuda performance
  • Obtain sales forecast for Latuda from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Key Topics Covered:

1 List of Tables

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.2 Treatment Overview

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Latuda (lurasidone hydrochloride)

6.1 Overview

6.2 Efficacy

6.3 Safety

6.4 SWOT Analysis

6.5 Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/v246fr/latuda

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System